Author

C. A. Fielding

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. J. Stanton· 3 shared A. J. Davison· 2 shared E. C. Y. Wang· 2 shared E. Wang· 2 shared J. Nichols· 2 shared K. Ladell· 2 shared K. Nightingale· 2 shared L. Nobre· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

R. J. Stanton

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways

A. Rubina, M. Patel, K. Nightingale, M. Potts, C. A. Fielding, S. Kollnberger, B. Lau, K. Ladell, K. L. Miners, J. Nichols, L. Nobre, D. Roberts, T. M. Trinca, J. P. Twohig, V.-M. Vlahava, , E. C. Y. Wang

This paper identifies how HCMV targets ADAM17 to modulate surface proteins and immune pathways, revealing a novel viral immunomodulation strategy.

bioRxiv · Mar 16, 2023Microbiology

Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies

M. D. Grant, K. Bentley, C. A. Fielding, K. M. Hatfield, D. P. Ings, D. Harnum, E. Wang, R. Stanton, K. A. Holder

This study shows that hybrid immunity, from prior infection followed by vaccination, generates stronger and broader antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 variants than vaccination alone.

bioRxiv · Mar 9, 2023 · PreprintImmunology

Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex

K. Nightingale, C. A. Fielding, C. Zerbe, L. Hunter, M. Potts, A. Fletcher-Etheringon, L. Nobre, E. C. Y. Wang, B. L. Strang, J. Houghton, R. Antrobus, N. M. Suarez, J. Nichols, A. J. Davison, R. J. Stanton, M. P. Weekes

This study identifies HCMV protein RL1 as a viral antagonist that degrades SLFN11 via CRL4 E3 ubiquitin ligase, revealing SLFN11's role in restricting HCMV infection.

bioRxiv · May 14, 2021Microbiology

ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies

C. A. Fielding, P. Sabberwal, J. C. Williamson, E. J. Greenwood, E. Crozier, W. Zelek, J. Seow, C. Graham, I. Huettner, J. Edgeworth, B. P. Morgan, K. Ladell, M. Eberl, I. R. Humphreys, B. Merrick, , R. J. Stanton

This study identifies ADNKA as a mechanism by which SARS-CoV-2-infected cells evade NK cell inhibition, showing that non-spike antibodies drive sustained NK activation and cytokine production.

bioRxiv · Apr 6, 2021Immunology